U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Hepatitis D, Chronic

MedGen UID:
105624
•Concept ID:
C0524911
•
Disease or Syndrome
Synonyms: Chronic Delta Hepatitides; Chronic Delta Hepatitis; Chronic Hepatitis D; Delta Hepatitides, Chronic; Delta Hepatitis, Chronic; Hepatitides, Chronic Delta; Hepatitis, Chronic Delta

Definition

INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS in conjunction with HEPATITIS B VIRUS and lasting six months or more. [from MeSH]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVHepatitis D, Chronic

Professional guidelines

PubMed

Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.
Ghany MG, Buti M, Lampertico P, Lee HM; 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference Faculty
J Hepatol 2023 Nov;79(5):1254-1269. Epub 2023 Jun 21 doi: 10.1016/j.jhep.2023.06.002. PMID: 37377088
EASL Clinical Practice Guidelines on hepatitis delta virus.
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver
J Hepatol 2023 Aug;79(2):433-460. Epub 2023 Jun 24 doi: 10.1016/j.jhep.2023.05.001. PMID: 37364791
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.
Ghany MG, Buti M, Lampertico P, Lee HM; 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference Faculty
Hepatology 2023 Nov 1;78(5):1654-1673. Epub 2023 Jun 21 doi: 10.1097/HEP.0000000000000431. PMID: 37326326

Recent clinical studies

Etiology

Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D.
Asselah T, Chulanov V, Lampertico P, Wedemeyer H, Streinu-Cercel A, Pântea V, Lazar S, Placinta G, Gherlan GS, Bogomolov P, Stepanova T, Morozov V, Syutkin V, Sagalova O, Manuilov D, Mercier RC, Ye L, Da BL, Chee G, Lau AH, Osinusi A, Bourliere M, Ratziu V, Pol S, Hilleret MN, Zoulim F
N Engl J Med 2024 Jul 11;391(2):133-143. Epub 2024 Jun 6 doi: 10.1056/NEJMoa2314134. PMID: 38842520
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.
Ghany MG, Buti M, Lampertico P, Lee HM; 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference Faculty
J Hepatol 2023 Nov;79(5):1254-1269. Epub 2023 Jun 21 doi: 10.1016/j.jhep.2023.06.002. PMID: 37377088
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.
Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Manuilov D, Suri V, An Q, Da B, Flaherty J, Osinusi A, Liu Y, Merle U, Schulze Zur Wiesch J, Zeuzem S, Ciesek S, Cornberg M, Lampertico P; MYR 301 Study Group
N Engl J Med 2023 Jul 6;389(1):22-32. Epub 2023 Jun 22 doi: 10.1056/NEJMoa2213429. PMID: 37345876
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.
Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, Sagalova O, Chulanov V, Osipenko M, Morozov V, Geyvandova N, Sleptsova S, Bakulin IG, Khaertynova I, Rusanova M, Pathil A, Merle U, Bremer B, Allweiss L, Lempp FA, Port K, Haag M, Schwab M, Zur Wiesch JS, Cornberg M, Haefeli WE, Dandri M, Alexandrov A, Urban S
Lancet Infect Dis 2023 Jan;23(1):117-129. Epub 2022 Sep 13 doi: 10.1016/S1473-3099(22)00318-8. PMID: 36113537
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(‡).
Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty
J Hepatol 2020 Mar;72(3):539-557. Epub 2019 Nov 12 doi: 10.1016/j.jhep.2019.11.003. PMID: 31730789

Diagnosis

Hepatitis D: A Review.
Negro F, Lok AS
JAMA 2023 Dec 26;330(24):2376-2387. doi: 10.1001/jama.2023.23242. PMID: 37943548
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.
Ghany MG, Buti M, Lampertico P, Lee HM; 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference Faculty
J Hepatol 2023 Nov;79(5):1254-1269. Epub 2023 Jun 21 doi: 10.1016/j.jhep.2023.06.002. PMID: 37377088
Targeting Hepatitis D.
Rizzetto M
Semin Liver Dis 2018 Feb;38(1):66-72. Epub 2018 Feb 22 doi: 10.1055/s-0037-1621711. PMID: 29471567
Chronic Hepatitis B, C, and D.
Cobb BR, Valsamakis A
Microbiol Spectr 2016 Aug;4(4) doi: 10.1128/microbiolspec.DMIH2-0025-2015. PMID: 27726758
Therapy of Delta Hepatitis.
Yurdaydin C, Idilman R
Cold Spring Harb Perspect Med 2015 Aug 7;5(10) doi: 10.1101/cshperspect.a021543. PMID: 26253093Free PMC Article

Therapy

Hepatitis D: A Review.
Negro F, Lok AS
JAMA 2023 Dec 26;330(24):2376-2387. doi: 10.1001/jama.2023.23242. PMID: 37943548
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.
Ghany MG, Buti M, Lampertico P, Lee HM; 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference Faculty
J Hepatol 2023 Nov;79(5):1254-1269. Epub 2023 Jun 21 doi: 10.1016/j.jhep.2023.06.002. PMID: 37377088
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.
Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Manuilov D, Suri V, An Q, Da B, Flaherty J, Osinusi A, Liu Y, Merle U, Schulze Zur Wiesch J, Zeuzem S, Ciesek S, Cornberg M, Lampertico P; MYR 301 Study Group
N Engl J Med 2023 Jul 6;389(1):22-32. Epub 2023 Jun 22 doi: 10.1056/NEJMoa2213429. PMID: 37345876
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(‡).
Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty
J Hepatol 2020 Mar;72(3):539-557. Epub 2019 Nov 12 doi: 10.1016/j.jhep.2019.11.003. PMID: 31730789
Targeting Hepatitis D.
Rizzetto M
Semin Liver Dis 2018 Feb;38(1):66-72. Epub 2018 Feb 22 doi: 10.1055/s-0037-1621711. PMID: 29471567

Prognosis

Hepatitis D: A Review.
Negro F, Lok AS
JAMA 2023 Dec 26;330(24):2376-2387. doi: 10.1001/jama.2023.23242. PMID: 37943548
Epidemiology, presentation, and therapeutic approaches for hepatitis D infections.
Blaney H, Khalid M, Heller T, Koh C
Expert Rev Anti Infect Ther 2023 Feb;21(2):127-142. Epub 2022 Dec 28 doi: 10.1080/14787210.2023.2159379. PMID: 36519386Free PMC Article
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(‡).
Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty
J Hepatol 2020 Mar;72(3):539-557. Epub 2019 Nov 12 doi: 10.1016/j.jhep.2019.11.003. PMID: 31730789
HBV/HDV Coinfection: A Challenge for Therapeutics.
Koh C, Da BL, Glenn JS
Clin Liver Dis 2019 Aug;23(3):557-572. Epub 2019 May 24 doi: 10.1016/j.cld.2019.04.005. PMID: 31266627Free PMC Article
Chronic viral hepatitis.
Chang MH
Indian J Pediatr 1995 Nov-Dec;62(6):673-9. doi: 10.1007/BF02825113. PMID: 10829942

Clinical prediction guides

Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma.
Giannini EG, Pasta A, Pieri G, Plaz Torres MC, Marseglia M, Pelizzaro F, Sangiovanni A, Cabibbo G, Ghittoni G, Di Marco M, Foschi FG, Guarino M, Biasini E, Saitta C, Campani C, Svegliati-Baroni G, Gasbarrini A, Brunetto MR, Magalotti D, Azzaroli F, Mega A, Sacco R, Nardone G, Sacerdoti D, Masotto A, Vidili G, Bucci L, Vitale A, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group
Liver Int 2024 Jul;44(7):1588-1599. Epub 2024 Mar 1 doi: 10.1111/liv.15855. PMID: 38426262
Hepatitis D: A Review.
Negro F, Lok AS
JAMA 2023 Dec 26;330(24):2376-2387. doi: 10.1001/jama.2023.23242. PMID: 37943548
The changing context of hepatitis D.
Rizzetto M, Hamid S, Negro F
J Hepatol 2021 May;74(5):1200-1211. Epub 2021 Jan 20 doi: 10.1016/j.jhep.2021.01.014. PMID: 33484770
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(‡).
Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty
J Hepatol 2020 Mar;72(3):539-557. Epub 2019 Nov 12 doi: 10.1016/j.jhep.2019.11.003. PMID: 31730789
Chronic Hepatitis B, C, and D.
Cobb BR, Valsamakis A
Microbiol Spectr 2016 Aug;4(4) doi: 10.1128/microbiolspec.DMIH2-0025-2015. PMID: 27726758

Recent systematic reviews

Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
Gish RG, Wong RJ, Di Tanna GL, Kaushik A, Kim C, Smith NJ, Kennedy PTF
Hepatology 2024 May 1;79(5):1129-1140. Epub 2023 Oct 23 doi: 10.1097/HEP.0000000000000642. PMID: 37870278Free PMC Article
Comparative effectiveness of seven interventions for chronic hepatitis D: a systematic review and network meta-analysis of randomized controlled trials.
Rong Y, Ju X, Sun P, Wang Y
BMC Infect Dis 2023 Oct 25;23(1):726. doi: 10.1186/s12879-023-08718-7. PMID: 37880598Free PMC Article
Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
Alfaiate D, Clément S, Gomes D, Goossens N, Negro F
J Hepatol 2020 Sep;73(3):533-539. Epub 2020 Mar 6 doi: 10.1016/j.jhep.2020.02.030. PMID: 32151618
Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature.
Fusco F, D'Anzeo G, Rossi A, Sciorio C, Buonomo AR, d'Emmanuele di Villa Bianca R, Borgia G, Mirone V, Gentile I
Expert Opin Pharmacother 2013 Dec;14(18):2533-44. Epub 2013 Nov 12 doi: 10.1517/14656566.2013.850073. PMID: 24215104
Interferon alpha for chronic hepatitis D.
Abbas Z, Khan MA, Salih M, Jafri W
Cochrane Database Syst Rev 2011 Dec 7;2011(12):CD006002. doi: 10.1002/14651858.CD006002.pub2. PMID: 22161394Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • MeSH
      Related Medical Subject Headings
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On
    • Hepatitis D, Chronic
      Hepatitis D, Chronic
      MedGen
    • Arterivirus Infections
      Arterivirus Infections
      Infections caused by viruses of the genus ARTERIVIRUS.<br/>Year introduced: 1994
      MeSH
    • Hepatitis E
      Hepatitis E
      Acute INFLAMMATION of the LIVER in humans; caused by HEPATITIS E VIRUS, a non-enveloped single-stranded RNA virus. Similar to HEPATITIS A, its incubation period is 15-60 days ...<br/>Year introduced: 1992
      MeSH
    • Spermatogenic failure, Y-linked, 2
      Spermatogenic failure, Y-linked, 2
      MedGen
    • Orthomyxoviridae Infections
      Orthomyxoviridae Infections
      Virus diseases caused by the ORTHOMYXOVIRIDAE.<br/>Year introduced: 1994
      MeSH

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...